GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Brain+ AS (OCSE:BRAINP) » Definitions » Current Deferred Revenue

Brain+ AS (OCSE:BRAINP) Current Deferred Revenue : kr0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Brain+ AS Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Brain+ AS's current deferred revenue for the quarter that ended in Dec. 2023 was kr0.00 Mil.

Brain+ AS Current Deferred Revenue Historical Data

The historical data trend for Brain+ AS's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brain+ AS Current Deferred Revenue Chart

Brain+ AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
- - - - -

Brain+ AS Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Deferred Revenue Get a 7-Day Free Trial - - - - -

Brain+ AS Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Brain+ AS's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Brain+ AS (OCSE:BRAINP) Business Description

Traded in Other Exchanges
N/A
Address
Kobmagergade 53, 3rd Floor, Copenhagen, DNK, DK-1150
Brain+ AS is a digital therapeutics company. It restores patients' quality of life by treating and detecting a cognitive decline in Alzheimer's disease and dementia through digital means. It has developed a set of Digital Medicine technologies. Its product pipeline includes CST Therapist Companion, and CST Home Companion; CST Home Care; CST for Mild Cognitive Impairment (MCI).

Brain+ AS (OCSE:BRAINP) Headlines

No Headlines